ESSA Pharma (EPI) Raised to “Buy” at Bloom Burton

Bloom Burton upgraded shares of ESSA Pharma (CVE:EPI) from a hold rating to a buy rating in a research note issued to investors on Thursday morning.

ESSA Pharma (EPI) opened at C$0.30 on Thursday. The company has a market capitalization of $8.72 and a PE ratio of -1.43. ESSA Pharma has a twelve month low of C$0.22 and a twelve month high of C$4.60.

ESSA Pharma (CVE:EPI) last announced its earnings results on Monday, December 11th. The company reported C($0.11) EPS for the quarter.

TRADEMARK VIOLATION NOTICE: “ESSA Pharma (EPI) Raised to “Buy” at Bloom Burton” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/01/21/essa-pharma-epi-raised-to-buy-at-bloom-burton.html.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit